Protein C and protein S deficiencies may be related to survival among hemodialysis patients

Mayuri Ichinose 1*, Naru Sasagawa 2, Tetsuo Chiba 2, Katsuhide Toyama 3, Yuzo Kayamori 4 and Dongchon Kang 5

Abstract

Background: Thrombophilia due to protein C (PC) and protein S (PS) deficiencies is highly prevalent among patients with stage 5 chronic kidney disease and is reported to arise due to extracorporeal circulation during hemodialysis (HD). This study aimed to evaluate the relationship between HD treatment and thrombophilia.

Methods: A total of 114 Japanese patients on maintenance HD (62 men, 52 women) were followed during 2008–2011. Their survival rates were compared against the duration of HD. Prior to each HD, coagulation/fibrinolysis parameters and PC and PS activities were measured using standard techniques. The patients were divided into two groups: Group 1, with PC and/or PS deficiencies (n = 32), and Group 2, without PC and PS deficiencies (n = 82). The influence of such deficiencies and duration of dialysis on survival was examined. Time-to-event analysis was applied using Kaplan-Meier estimates, and the log-rank test was proposed to test the equivalence of relative survival data. Hazard ratios and 95% confidence intervals (CI) were calculated.

Results: Of the 114 patients, 37 died (Group 1, 22; Group 2, 15). The hazard ratio (95% CI) was higher (p = 0.004) in Group 1 than Group 2. Gene analyses of PC and PS were performed in 14 patients from Group 1. No mutations in either protein were observed. We analyzed the causes of death in both groups; however, the estimated thrombophilia-related incidence of death could not be determined due to small sample size of HD patients.

Conclusions: Our results suggest that PC and PS deficiencies may be related to survival in HD patients. However, this finding warrants additional research.

Keywords: Hemodialysis patients, Protein C, Protein S, Thrombophilia

Background

Chronic kidney disease (CKD) is a global health burden affecting 7% of people aged > 30 years and 25–35% of people aged > 65 years [1]. In patients who require hemodialysis (HD), the glomerular filtration rate is reduced to 10–15% [2]. Several studies have revealed that HD patients are at high risk of cardiovascular disease (CVD) [3]. CVD incidence is significantly higher among HD patients, with mortality rates 10–20 times greater than those of the general population [1]. Patients on maintenance HD experience thrombotic events that frequently occur at the site of vascular access as well as in the coronary, cerebral, and retinal arteries [4, 5]. Thrombosis-related cardiovascular events are well-known dominant causes of death and account for the majority of morbidities in end-stage renal disease (ESRD) patients [6]. Cardiovascular events have several risk factors, including lipoproteinemia, chronic inflammation, hypertension, oxidative stress, elevated homocysteine level, and anemia. These factors may contribute to the increased frequency of critical complications in CKD patients [7–9].

HD is a very specific procedure that involves the extracorporeal removal of excess fluid and waste products, including uremic toxins and creatinine, from the blood. CKD patients, especially those on HD, have a hypercoagulable state [10, 11]. HD-associated thrombosis occurs frequently in the clinical field, and the association between HD and thrombosis could be a causal relationship.
However, the mechanism remains unclear. Thrombosis involves various genetic and environmental factors. Under normal physiological conditions, the mechanism of coagulation control works in a multilevel cascade to prevent clot formation in blood vessels, and coagulation reactions do not occur excessively even if the blood vessels are injured. In HD, the blood circuit resembles a condition of artificially injured vessels, and some studies report that deficiency in the coagulation inhibition of protein C (PC) and protein S (PS), which are regulators of physiological coagulation, poses a risk for thrombus formation. It is well known that there are many more dialysis patients with a history of long-term HD in Japan compared to those in European countries and the United States. While preparing for this study, our preliminary findings seem to suggest an abnormal association between PC and PS activities and duration of HD and that long-term HD patients have normal or high PC and PS activity levels. Therefore, in this study, we aimed to evaluate PC and PS activity in HD patients retrospectively; we also assessed the patients over a 3-year follow-up period to clarify how this association affected their survival.

Methods
A total of 114 patients on HD were enrolled in this study and followed up from October 2008 to December 2011. Their characteristics, including the cause of ESRD and duration of hemodialysis, are shown in Table 1. All patients were dialyzed using primary arteriovenous fistulas (AVFs); there were no arteriovenous grafts (AVGs) and artificial devices. No patients were taking drugs known to interact with PC and PS activities such as warfarin, at the starting point. All patients received conventional HD with bicarbonate bath thrice a week and underwent dialysis using a polysulfone membrane when they were enrolled. Heparin was used as an anticoagulant in all patients. Information was obtained from all patients about the family history of thrombotic related diseases, history of cerebral infarction, and also their social history such as smoking, drinking, or medications other than those related to HD.

The study protocol was verified and approved by the institutional review board of Kyushu University. Written informed consent was obtained from all patients, and all clinical investigations were conducted according to the principles laid down in the Declaration of Helsinki. The patients gave consent for the publication of clinical details.

Laboratory investigations
Venous blood samples were collected at the beginning of each week just after the start of HD before heparin injection, and various parameters were measured. Hematology parameters included hematocrit (Ht) and platelet count (Plt). Biochemistry parameters included serum creatinine (Cre), blood urea nitrogen (BUN), serum uric acid (UA), total cholesterol (T-Chol), and triglycerides (TG). Coagulation testing of plasma samples was performed using an automated blood coagulation analyzer. Coagulation parameters included prothrombin time (PT-T), prothrombin time percentage (PT %), prothrombin time - international normalized ratio (PT-INR), thrombo-test (TT), heparplastin test (HPT), and activated partial thromboplastin time (APTT). PC activity was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit, whereas PS was measured as described previously.

Statistical analysis
Students’ paired t-test was used for parametric data, and multivariate analyses were performed with logistic analyses to determine the significance of differences between groups. All analyses were performed using SPSS Statistics version 23 (IBM Corp., Armonk, NY, USA). Clinical data were expressed as mean values ± standard deviation and as prevalence rates. Statistical significance was taken at or below the 5% level. Time-to-event analysis was applied using Kaplan-Meier estimates, and the log-rank test was proposed to test the equivalence of relative survival data. Hazard ratios and 95% confidence intervals (CI) were calculated.
Results
We divided the patients with PC and PS activity into two groups: Group 1 consisted of 32 patients with decreased PC and PS activities, and Group 2 consisted of 82 patients with PC or PS activities either within the normal range or increased.

The causes of renal failure that led to ESRD among the patients are shown in Table 2. In Group 1, the causes included chronic glomerulonephritis (CGN) (25%), diabetes mellitus (DM) (62.5%), polycystic kidney (PK) (3%), and focal glomerulosclerosis (FGS) (9.4%). In Group 2, the causes were CGN (29.3%), DM (51.2%), PK (3.7%), and FGS (13.4%).

Both groups showed similar levels of blood and biochemical parameters (Ht, Plt, Cre, BUN, UA, T-Chol, and TG) (Table 3), demonstrating no significant differences (p = 0.05). There were also no significant differences in blood coagulation parameters between the patients in Group 1 and Group 2 who underwent the blood coagulation test (p = 0.05) (Table 4).

In both groups of patients, there was family history of myocardial infarction (MI) (Group 1, 9%; Group 2, 10%); cerebrovascular disease (CVD) (Group 1, 24%; Group 2, 19%); deep vein thrombosis (DVT) (Group 1, 2%; Group 2, 3%); and peripheral artery disease (PAD) (Group 1, 3%; Group 2, 2%). The patients also had past medical history of MI (Group 1, 10%; Group 2, 9%); CVD (Group 1, 8%; Group 2, 7%); DVT (Group 1, 5%; Group 2, 6%); pulmonary embolism (Group 1, 3%; Group 2, 1%); and PAD (Group 1, 3% Group 2, 3%). There was no significant difference between the groups in terms of duration of HD. No obvious relationship was noted with other factors such as smoking, drinking, and medications, between Groups 1 and 2. During the 3-year follow-up, 36 patients died.

Table 2 Basic demographics and clinical characteristics of study patients

| Group | N = 32 | PC and/or PS activities were low |
|-------|--------|--------------------------------|
| Group 1 | 32     | Both PC and PS activities were normal |
| Group 2 | 82     |                                   |

Table 3 Blood and biochemical parameters

|                      | Group 1   | Group 2   | p-value |
|----------------------|-----------|-----------|---------|
| Ht %                 | 28.6 ± 3.17 | 28.85 ± 2.86 | NS      |
| Plt x 10^3           | 20.56 ± 7.56 | 21.99 ± 7.45 | NS      |
| BUN mg/dL            | 72.23 ± 14.9 | 73.39 ± 15.27 | NS      |
| Cre mg/dL            | 12.4 ± 1.86  | 12.57 ± 2.94  | NS      |
| UA mg/dL             | 8.38 ± 1.29  | 8.06 ± 1.41   | NS      |
| Ca mg/dL             | 9.88 ± 0.89  | 9.92 ± 1.01   | NS      |
| Pi mg/dL             | 5.87 ± 0.97  | 5.78 ± 1.26   | NS      |
| T-Chol mg/dL         | 162.48 ± 34.23 | 172.63 ± 41.33 | NS      |
| TG mg/dL             | 155.96 ± 96.25 | 152.93 ± 91.11 | NS      |

A 3-year follow-up after the blood tests revealed that Group 1 had significantly higher mortality rates than Group 2. The Kaplan-Meier survival analysis showed a significant difference in all-cause mortality between both groups (p = 0.004, by the log-rank test) (Fig. 1). Causes of death in the 37 patients included heart failure (Group 1, 8; Group 2, 6); cerebral vascular disease (Group 1, 3; Group 2, 4); pneumonia (Group 1, 3; Group 2, 3); and unknown (Group 1, 8; Group 2, 2).

Gene analyses were performed in 14 patients from Group 1, who provided informed consent and agreement to undergo a gene mutation screening of PC and PS. However, no mutations in either protein were observed.

Discussion
According to the US Renal Data System and the Die Deutsche Diabetes Dialyse Studie (4D Study), approximately 50% of deaths among HD patients are from cardiovascular causes [15]. However, cardiovascular events could be diverse and related to other factors especially in HD patients. In this study, we observed that PC and/P

Table 4 Blood coagulation parameters

|                      | Group 1     | Group 2     | p-value |
|----------------------|-------------|-------------|---------|
| PT-T sec             | 12.29 ± 1.05 | 12.54 ± 2.30 | NS      |
| PT %                 | 87.9 ± 15.88 | 86.08 ± 16.27 | NS      |
| PT-INR 1.07 ± 0.97   | 1.1 ± 0.21   | NS          |
| TT %                 | 99.09 ± 6.51 | 96.26 ± 14.94 | NS      |
| HPT %                | 115.23 ± 11.96 | 114.45 ± 16.77 | NS      |
| APTT sec             | 35.76 ± 5.89 | 37.44 ± 12.2 | NS      |
| Fibrinogen mg/dL     | 320.23 ± 107.16 | 296.93 ± 97.24 | NS      |
| PC activity %        | 38.78 ± 20.29* | 97.02 ± 17.71 | < 0.01 |
| PS activity %        | 34.16 ± 26.56* | 81.38 ± 19.95 | < 0.01 |

NS not significant, PT-T prothrombin time, PT% prothrombin percentage, PT- INR prothrombin time - international normalized ratio, TT thrombostest, HPT heparin test, APTT activated partial thromboplastin time, PC protein C, PS protein S

*p < 0.01 vs Group 2 (analysis of variance)
or PS activities decreased in some HD patients (Group 1). HD patients (Group 1) also had significantly higher mortality rates than those with normal PC and PS activities (Group 2) during the 3-year follow-up. Moreover, no PC and PS gene mutations were found in Group 1. One study showed the recovery of PC activity after renal transplantation [16]. This could be explained by the interplay between blood and dialyzer membrane surfaces and the use of anticoagulants in the HD circuit. These factors induce acute and chronic activation of platelets, resulting in platelet exhaustion along with consumption of PC and PS [17]. Furthermore, the duration of HD was longer in Group 1 than in Group 2, which might have led to the decrease in PC and PS activities in Group 1 due to dissipation of these proteins in the HD circuit. A study from Japan showed that the duration of HD in HD patients is a significant independent risk factor for mortality [18].

Patients with chronic renal failure have a high prevalence of systemic inflammation and diffuse endothelial damage [19]. The endothelium modulates the systemic coagulation cascade by inhibiting activated coagulation factors, such as V and VIII, through the PC and PS pathway. The pathway starts when thrombin binds to endothelial cell receptors on the endothelial cell surface [20]. Endothelial injury results in decreased levels of membrane-bound thrombomodulin and increased levels of soluble thrombomodulin in the plasma [21]. This could be attributed to a decrease in PC activity. PC deficiency can occur during acute thrombosis or when the patient is undergoing anticoagulation. However, this possibility is low in the present study because the values of blood coagulation and hematology parameters were similar in both groups. Plasma levels of PC were reported to be significantly lower in HD patients with thrombotic complications than in those without thrombotic complications [22]. Moreover, the levels of anti-PC and anti-PS antibodies were significantly higher in HD patients with vascular access thrombosis than in those without vascular access thrombosis [23].

HD patients were reported to have a family history of CKD or ESRD and a higher risk for developing these conditions [24], and the leading cause of death among HD patients is cardiovascular disease [6]. Additionally, the presence of a residual thrombus after the first episode of DVT is an independent risk factor for recurrence [25]. Stable ischemic heart disease and previous MI are also well known to easily exacerbate the risk of recurrent cardiovascular events [26]. Recently, some studies have evaluated different risk factors for thrombophilia in HD patients [17, 27]. In the present study, both groups of HD patients also reported a high prevalence of CVD and MI in their family and medical histories, and a high morbidity of CVD. Therefore, transfer to another clinic or hospital was required. This prevented us from tracking their medical condition and dialysis activity in detail, and added to the difficulty in analyzing some of the factors. Because dialysis is a treatment by specialists from different fields, further research on HD patients with thrombophilia within a multidisciplinary cooperative system is required.

Our study included only HD patients and therefore these results do not reflect causes of thrombophilia-related death. Additional large-scale research is required, especially among nephritis and chronic renal failure patients, to further clarify the unknown risk factors of thrombophilia among such patients.

**Conclusions**

In conclusion, PC and PS deficiencies are not only associated with vascular access thrombosis [28] but may also be related to survival among HD patients. It is important that the PC and PS activities, in addition to thrombophilia, among HD patients be carefully monitored, in particular, by clinicians and experts in hematology and nephrology.

**Abbreviations**

- APTT: Activated partial thromboplastin time;
- BUN: Blood urea nitrogen;
- CKD: Chronic kidney disease;
- Cre: Creatinine;
- ELISA: Enzyme-linked immunosorbent assay;
- HD: Hemodialysis;
- HPT: Hepaplastin test;
- Ht: Hematocrit;
- INR: International normalized ratio;
- MI: Myocardial infarction;
- PC: Protein C;
- Plt: Platelet count;
- PS: Protein S;
- PT %: Prothrombin time percentage;
- PT-T: Prothrombin time;
- T-Cho: Total cholesterol;
- TG: Triglycerides;
- TT: Thrombo-test;
- UA: Serum uric acid;

**Fig. 1** Survival curves calculated using the Kaplan-Meier method according to the duration of analysis.
Acknowledgments
We thank Emeritus Professor Naotaka Harasaki of Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan, for his help in interpreting the results of this study. We also thank Emeritus Professor Hiroshi Nihei of Tokyo Women’s Medical University, Tokyo, Japan for his useful advice on research design.

Funding
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors’ contributions
MI designed the study and wrote the initial draft of the manuscript. KT contributed to the analysis and interpretation of data and assisted in the preparation of the manuscript. All other authors contributed to data collection and interpretation and critically reviewed the manuscript. All authors read and approved the final version of the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate
The study protocol was verified and approved by the institutional review board of Kyushu University. Written informed consent was obtained from all patients. The patients gave consent for the publication of clinical details.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-ku, Tokyo 105-8461, Japan. 2Vascular Access Center, Yokohama Dai-ichi Hospital, Yokohama, Japan. 3Department of Internal Medicine, Yokohama Dai-ichi Hospital, Yokohama, Japan. 4Department of Health Sciences, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan. 5Department of Clinical Chemistry and Laboratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Received: 7 November 2018 Accepted: 18 April 2019
Published online: 28 May 2019

References
1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
2. Kidney Disease. Improving global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3:1–150.
3. Lindner A, Charna B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697–701.
4. Cheung AK, Sannak MJ, Yan G, Dwyer JT, Heyka RJ, Rocco MV, et al. Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients. Kidney Int. 2003;59:533–62.
5. Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population the CHOICE study. J Am Soc Nephrol. 2002;13:1918–27.
6. Goodkin DA, Young EW, Kurokawa K, Prütz KG, Levin NW. Mortality among hemodialysis patients in Europe, Japan, and the United States: case-mix effects. Am J Kidney Dis. 2004;44:516–21.
7. Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in chronic renal failure. Lancet. 2003;356:147–52.
8. Di Angelantonio E, Chowdhury R, Sarwar N, Aspelund T, Danesh J, Gudnason V. Chronic kidney disease and risk of major cardiovascular disease and non-vascular mortality: prospective population based cohort study. BMJ. 2010;341:c4986.
9. Kimmel PL, Phillips TM, Simmens SJ, Peterson RA, Weihls KL, Alleyne S, et al. Immunologic function and survival in hemodialysis patients. Kidney Int. 1998;54:236–44.
10. Madhusudhan T, Kerlin BA, Iserrmann B. The emerging role of coagulation proteins in kidney disease. Nat Rev Nephrol. 2016;12:94–109.
11. Tangvoraphonkhai K, Riddell A, Davenport A. Platelet activation and clotting cascade activation by dialyzer designs for high volume online hemodiafiltration. Hemodial Int. 2018;22:192–200.
12. Mahmoodi BK, Veeger NJ, Middeldorp S, Lijfering WM, Brouwer JL, ten Berg J, et al. Interaction of hereditary thrombophilia and traditional cardiovascular risk factors on the risk of arterial thromboembolism: pooled analysis of four family cohort studies. Circ Cardiovasc Genet. 2016;9:79–85.
13. Lijfering WM, Brouwer JL, Veeger NJ, Bank J, Coppens M, Middeldorp S, et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood. 2009;113:5314–22.
14. Tsuda T, Jin X, Tsuda H, Ieko M, Morishita E, Adachi T, et al. New quantitative total protein S assay system for diagnosing protein S type II deficiency: clinical application of the screening system for protein S type II deficiency. Blood Coagul Fibrinolysis. 2012;23:56–63.
15. Ritz E, Bommer J. Cardiovascular problems on hemodialysis: current deficits and potential improvement. Clin J Am Soc Nephrol. 2009;4:571–8.
16. Ghidial L, Broeders N, Wissing KM, Mena JM, Lemy A, Lemi W, et al. Thrombophilic factors in stage V chronic kidney disease patients are largely corrected by renal transplantation. Nephrol Dial Transplant. 2011;26:2700–5.
17. Knoll GA, Wells PS, Young D. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol. 2005;16:1108–14.
18. Iseli K, Tozawa M, Takishita S. Effect of the duration of dialysis on survival in a cohort of chronic haemodialysis patients. Nephrol Dial Transplant. 2003;18:782–7.
19. Spittle MA, Hoenich NA, Handelman GJ, Adhikaria R, Homel P, Levin NW. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis. 2001;38:1408–13.
20. Previtali E, Buciarelli P, Passamonti SM, Martellini I. Risk factors for venous and arterial thrombosis. Blood Transfus. 2011;9:120–38.
21. Keven K, Elmaci S, Sengul S, Akar N, Egin Y, Gene V, et al. Soluble endothelial cell protein C receptor and thrombomodulin levels after renal transplantation. Int Urol Nephrol. 2010;42:1093–8.
22. Inoue A, Wada H, Takagi M, Yamamura M, Mukai K, Nakasaki T, et al. Hemostatic abnormalities in patients with thrombotic complications on maintenance hemodialysis. Clin Appl Thromb Hemost. 2000;6:100–3.
23. Molino D, De Lucia D, Marotta R, Perna A, Lombardi C, Cirillo M, et al. In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney Int. 2005;68:1223–9.
24. Huang JC, Chen SC, Lin MY, Chang JM, Hwang SJ, Tsai JC, et al. Association of relatives of hemodialysis patients with metabolic syndrome, albuminuria and Framingham risk score. PLoS One. 2014;9:e96362.
25. Kearon C. Natural history of venous thromboembolism. Circulation. 2003;107:122–31.
26. Eagle KA, Hirsch AT, Califf RM, Alberts MJ, Stieg PG, Cannon CP, et al. Cardiovascular ischemic event rates in outpatients with symptomatic atherothrombosis or risk factors in the United States: insights from the REACH registry. Circ Pathw Cardiol. 2009;8:89–7.
27. Sharma S, Farrington K, Kozarci R, Christopoulou C, Niespielowska-Steudan M, Moffat D, et al. Impaired thrombolysis: a novel cardiovascular risk factor in end-stage renal disease. Eur Heart J. 2013;34:634–63.
28. Mörtberg J, Blombäck M, Wallén Å, Je S, Jacobson SH, Spaak J. Increased fibrin formation and impaired fibrinolytic capacity in severe chronic kidney disease. Blood Coagul Fibrinolysis. 2016;27:401–7.